0001415889-24-024384.txt : 20241002
0001415889-24-024384.hdr.sgml : 20241002
20241002161517
ACCESSION NUMBER: 0001415889-24-024384
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20241001
FILED AS OF DATE: 20241002
DATE AS OF CHANGE: 20241002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carson William H.
CENTRAL INDEX KEY: 0001824280
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 241347519
MAIL ADDRESS:
STREET 1: C/O PREVAIL THERAPEUTICS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 1520
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
form4-10022024_041010.xml
X0508
4
2024-10-01
0001528115
Annexon, Inc.
ANNX
0001824280
Carson William H.
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
true
false
false
false
1
Common Stock
2024-10-01
4
P
0
3200
5.97
A
22400
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024.
This transaction was executed in multiple trades in prices ranging from $5.765 to $6.16, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
/s/ Jennifer Lew, Attorney-in-Fact
2024-10-02